摘要
目的探讨新活素对冠心病介入患者血管内皮依赖性舒张功能、血浆NO含量的影响。方法选取2020年3月~2022年3月牡丹江医学院附属红旗医院收治的100例冠心病介入患者作为研究对象,按照随机数表法分为对照组和观察组,每组50例。对照组给予常规药物治疗(按照患者的临床表现及病情的特点给予患者制订合理的治疗方案,包括给予硝酸酯类药物、抗血小板药、抗凝药等),研究组在常规基础上给予新活素治疗。观察两组临床疗效、生化指标变化情况、血管内皮依赖性舒张功能(FMD)、血浆一氧化氮(NO)含量以及不良反应发生率。结果研究组患者治疗的总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者超敏C反应蛋白(hs-CRP)、B型利钠肽(BNP)与白细胞介素-6(IL-6)指标比较,差异无统计学意义(P>0.05);治疗后,研究组各项指标明显低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的FMD和血浆NO含量比较差异无统计学意义(P>0.05);治疗后,两组患者的FMD和血浆NO含量均升高且研究组FMD和血浆NO含量均高于对照组,差异有统计学意义(P<0.05)。研究组患者的不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论新活素用于冠心病介入患者治疗能够很好地提升FMD,改善心功能,增加血浆NO的含量,疗效显著,且不良反应发生率低、安全可靠,为冠心病的治疗提供了新的思路和治疗手段。
Objective To investigate the eff ects of lyophilized recombinant human brain natriuretic peptide on endothelium dependent vasodilation and plasma NO in patients with coronary artery disease(CAD)after percutaneous coronary intervention.Methods From March 2020 to March 2022,100 patients with coronary intervention who were admitted to the Hongqi Hospital affi liated to Mudanjiang Medical College were selected and divided into two groups(named study group and control group respectively)according to the random number table.The patients were treated with routine drugs(according to the clinical manifestations and characteristics of the disease,the patients were given a reasonable treatment plan,including nitrates,antiplatelet drugs,anticoagulants,etc.).The study group of 50 patients was treated with lyophilized recombinant human brain natriuretic peptide on a routine basis.The clinical effi cacy,changes in biochemical indicators,fl ow mediated dilation(FMD)Plasma(nitric oxide,NO)and the incidence of adverse reactions.Results The total eff ective rate of patients in the study group was signifi cantly higher than that in the control group(P<0.05).There was no signifi cant diff erence in hs-CRP,BNP and IL-6 between the two groups before treatment(P>0.05),after treatment,the indexes in the study group were signifi cantly lower than those in the control group(P<0.05).There was no signifi cant diff erence between the two groups in the levels of FMD and plasma NO before treatment(P>0.05),and after treatment,the levels of FMD and plasma NO in the two groups were both increased(P<0.05),and the levels of the above indicators in the study group were higher than those in the control group(P<0.05).The incidence of adverse reaction in the study group was lower than that in the control group(P<0.05).Conclusion Lyophilized recombinant human brain natriuretic peptide can improve endothelium dependent vasodilation function,improve cardiac function,increase plasma NO content in patients with coronary heart disease after intervention.It has signifi cant eff ect,and the incidence of adverse reactions is low.Furthermore,it is safe and reliable.It provides a new idea and treatment method for the treatment of coronary heart disease.
作者
谢骏
符北京
高凤敏
XIE Jun;FU Bei-jing;GAO Feng-min(Department of Cardiology,Hongqi Hospital Affiliated to Mudanjiang Medical College,Mudanjiang Heilongjiang,157011,China)
出处
《中华养生保健》
2022年第24期8-11,共4页
CHINESE HEALTH CARE
基金
黑龙江省自然科学基金联合引导项目(LH2019H120)。
关键词
新活素
冠心病
血管内皮依赖性舒张功能
血浆NO
lyophilized recombinant human brain natriuretic peptide
coronary heart disease
endothelium-dependent vasodilation
plasma NO